Imeik Technology Investment Quality Review (300896.SZ)

Data timestamp: 2026-08-03 22:13 UTC
Quality score: 85/100
Valuation position: current price/base FV 1.47
Final signal: WATCHLIST

Core Conclusion

Imeik has one of the highest quality scores in the batch, but the stock is still too expensive. CNY105.95 is 1.47x base FV of CNY72.04 and 2.43x conservative FV of CNY43.65, so the signal remains watchlist.

Business Breakdown

Five-year revenue CAGR is 22.1%, with latest-year revenue of CNY2.45bn. The aesthetic-medicine franchise shows premium economics, but demand cyclicality, regulation, product concentration, and channel quality require close tracking.

Business Quality

The 85/100 score is supported by high margins, strong returns, and cash generation. Latest-year FCF was CNY1.15bn. Five-year average ROE was 17.0% and average ROIC was 15.7%. Quality is not the issue; the price is.

Financial Audit

Fiscal 2025 revenue was CNY2.45bn, net profit CNY1.29bn, operating cash flow CNY1.32bn, capex CNY0.17bn, and FCF CNY1.15bn. Five-year FCF/net income was 0.91 and OCF/net income was 1.00. Latest net cash was CNY0.97bn.

Valuation

The conservative case uses CNY1.34bn normalized FCF, 2.0% growth, and 9.2x, producing CNY43.65 per share. The base case uses 4.0% growth and 15.6x, producing CNY72.04. The optimistic case uses 5.0% growth and 20.0x, producing CNY91.49. Current price is above even the optimistic case.

Buy And Tracking Discipline

The action is watch. Upgrade requires price/base FV below 0.70, quality above 75, repeatable FCF, and continued evidence that product demand, pricing, regulation, and channel economics remain intact.

Risk Review

Risks include medical-aesthetics regulation, product concentration, distributor behavior, consumer demand weakness, margin erosion, and capital allocation. Weak FCF conversion or net-cash deterioration would lower FV.

Data Sources

The memo relies on public market and financial data, company filings or investor-relations materials, ChinaBond yield data, and public FX data where applicable. This is research only, not personalized investment advice.